Shanghai, China, 28 December 2021 — MicroPort^® CardioFlow Medtech Corporation (MicroPort^® CardioFlow) recently announced that its latest transcatheter aortic valve implantation (TAVI) solution, the new-generation VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty™) has completed the submission of applications materials for the EU CE certification.

Shanghai, China, 5 November 2021 — MicroPort^® CardioFlow Medtech Corporation (CardioFlow Medtech) hosted a symposium for its next-generation transcatheter aortic valve implantation (TAVI) product, the VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty™), during the 32nd Great Wall International Congress of Cardiology (GW-ICC) and Asia Heart Society Congress. The event brought together experts in the field of structural heart disease to share their experience on the clinical application of VitaFlow Liberty™.

Shanghai, China, 5 November 2021 — MicroPort^® CardioFlow Medtech Corporation (02160.HK, MicroPort^® CardioFlow) is set to become the largest shareholder of 4C Medical Technologies, Inc. (4C Medical) following the recent completion of a series C preferred shares subscription agreement. As the lead investor of the round, MicroPort^® CardioFlow will make a strategic investment up to USD 25 million in 4C Medical, and will be granted the exclusive commercial rights to the investigational tricuspid products in China.